Allogeneic marrow transplantation in the treatment of preleukemia.

Abstract

Ten patients with preleukemia and life-threatening pancytopenia were treated with marrow transplantation. In all ten cases allogeneic marrow was successfully engrafted. In three patients prepared for transplantation with cyclophosphamide alone, the abnormal cell clone either persisted or reemerged within 6 months of transplantation. The other seven patients were treated with cyclophosphamide plus total body irradiation before transplantation and six of the seven are alive and well without evidence of disease from 7 to 25 months after transplantation. These results suggest that cyclophosphamide alone before marrow transplantation is incapable of eradicating the abnormal clone. Cyclophosphamide combined with total body irradiation appears more effective, although more time is needed for full evaluation of results. This experience also emphasizes the importance of performing chromosome studies before transplantation for pancytopenic states in order to identify cases of preleukemia.

• Authors: F R Appelbaum, R Storb, R E Ramberg, H M Shulman, C D Buckner, R A Clift, H J Deeg, A Fefer, J Sanders, P Stewart
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 100 Issue 5 Pg. 689-93 (May 1984) ISSN: 0003-4819 [Print] United States
• PMID: 6370066 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Cyclophosphamide

Topics

• Adolescent
• Adult
• Bone Marrow Examination
• Bone Marrow Transplantation
• Child
• Child, Preschool
• Combined Modality Therapy
• Cyclophosphamide (therapeutic use)
• Female
• Graft vs Host Disease (etiology)
• Humans
• Male
• Middle Aged
• Postoperative Complications
• Preleukemia (therapy)
• Preoperative Care
• Whole-Body Irradiation